Respirology (Carlton, Vic.)最新文献

Predictors and outcomes of respiratory bacterial coinfections in patients with COVID-19 admitted to hospital: An observational prospective study. COVID-19住院患者呼吸道细菌合并感染的预测因素和结局:一项观察性前瞻性研究

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-09-16 DOI: 10.1111/resp.14372

Giusy Tiseo, Lorenzo Roberto Suardi, Lisa Giusti, Arianna Forniti, Claudio Caroselli, Valentina Galfo, Sara Occhineri, Alessandro Leonildi, Giovanna Moscato, Francesco Menichetti, Marco Falcone

引用次数: 2

Dual bronchodilator treatment for prevention of COPD in at-risk smokers. 双重支气管扩张剂治疗预防高危吸烟者COPD。

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-09-11 DOI: 10.1111/resp.14357

Cindy Thamrin, Allison Martin, Tanya Badal, Edward Jeagal, Belinda Cochrane, Claude S Farah, Gregory G King, Mohan Nagarajah, Qiang Li, Xiaoqiu Liu, Norbert Berend, Christine R Jenkins

引用次数: 1

Cryotherapy in the paediatric airway: Indications, success and safety. 儿童气道冷冻治疗:适应症、成功和安全性。

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-08-28 DOI: 10.1111/resp.14353

Dirk Schramm, Nadine Freitag, Karsten Kötz, Ignacio Iglesias-Serrano, Mario Culebras-Amigo, Vladimir Koblizek, Santiago Pérez-Tarazona, Enrique Cases Viedma, J T Srikanta, Peter Durdik, Kaid Darwiche, Sune Rubak, Patrick Stafler

{"title":"Cryotherapy in the paediatric airway: Indications, success and safety.","authors":"Dirk Schramm, Nadine Freitag, Karsten Kötz, Ignacio Iglesias-Serrano, Mario Culebras-Amigo, Vladimir Koblizek, Santiago Pérez-Tarazona, Enrique Cases Viedma, J T Srikanta, Peter Durdik, Kaid Darwiche, Sune Rubak, Patrick Stafler","doi":"10.1111/resp.14353","DOIUrl":"https://doi.org/10.1111/resp.14353","url":null,"abstract":"Background and objective: Cryotherapy in interventional bronchoscopy is a new treatment modality, which has recently been made available for the paediatric airway. Lack of experience and safety concerns have led to hesitant adaptation. The aim of this study was to assess indications, success rates and complications of airway cryotherapy in children.Methods: Bronchoscopists from medical centre performing cryotherapy in patients between 0 and 18 years were invited to participate in a prospective study based on an online questionnaire. Patient and participant data were collected between June 2020 and June 2021.Results: A total of 69 cryotherapy procedures were performed in 57 patients a for three main indications: Biopsy (30), restoration of airway patency (23) and foreign body aspiration (16). The overall success rate was 93%, the remaining 7% were performed for foreign body removal and required a switch of technique. Restoration of airway patency was successfully applied in various pathologies, including mucus plugs, bronchial casts and post traumatic stenosis. The diagnostic yield of transbronchial biopsies was 96%. No severe complications were encountered; one pneumothorax following a cryobiopsy required a chest drain for 48 h. No child was admitted to intensive care or died from a procedural complication.Conclusion: In this largest paediatric case collection to date, cryotherapy was safe and carried a high success rate. Cryobiopsy compares favourably to the widely used forceps biopsy and could replace it in the future. Paediatric bronchoscopists are encouraged to add cryotherapy to their armamentarium of airway interventions.","PeriodicalId":162871,"journal":{"name":"Respirology (Carlton, Vic.)","volume":" ","pages":"966-974"},"PeriodicalIF":6.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40345103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Leading women in respiratory medicine and research: Opportunities for international societies to support women with examples from the American Thoracic Society. 呼吸医学和研究领域的领先女性:国际社会支持女性的机会(以美国胸科学会为例)

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-09-19 DOI: 10.1111/resp.14374

Meghan E Rebuli, Ilona Jaspers

引用次数: 0

Letter from New Zealand. 来自新西兰的信。

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-09-18 DOI: 10.1111/resp.14375

Tom Hills, Richard Beasley

{"title":"Letter from New Zealand.","authors":"Tom Hills, Richard Beasley","doi":"10.1111/resp.14375","DOIUrl":"https://doi.org/10.1111/resp.14375","url":null,"abstract":"infection already in place, REMAP-CAP was able to recruit its first COVID-19 patient on 9 March 2020, before the pandemic had been officially declared by the World Health Organization.Astempting as it may be to try to put the COVID-19 pandemic behind us, New Zealand ’ s preparedness for the next pandemic must be a priority and must focus on being science-led, using local and international expertise, and informed by research and reflection. It must be adaptable enough to respond to a range of different pathogens, with different characteristics, rather a single pathogen (as with New Zealand ’ s previous influenza-focused pandemic plan). It should consider what local capacities must be maintained between pandemics (e.g., surveillance and strong public health units), what resources must be available when required (e.g., isolation/quarantine facilities) and what addi-tional capacities may need to be developed in advance (e.g., vaccine manufacturing capability). A pandemic preparedness strategy must be designed to generate data so as research allows the response to ‘ learn ’ as we go. Another pandemic will occur and the short window likely to be afforded while the novel pathogen adapts to be transmit-ted efficiently among human hosts must be all the time it takes for a small, relatively isolated and relatively well-resourced country like New Zealand to respond effectively.","PeriodicalId":162871,"journal":{"name":"Respirology (Carlton, Vic.)","volume":" ","pages":"994-995"},"PeriodicalIF":6.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40365085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic obstructive pulmonary disease (COPD) mortality trends worldwide: An update to 2019. 全球慢性阻塞性肺疾病(COPD)死亡率趋势:2019年最新情况

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-07-13 DOI: 10.1111/resp.14328

Federico Mei, Michela Dalmartello, Martina Bonifazi, Paola Bertuccio, Fabio Levi, Paolo Boffetta, Eva Negri, Carlo La Vecchia, Matteo Malvezzi

{"title":"Chronic obstructive pulmonary disease (COPD) mortality trends worldwide: An update to 2019.","authors":"Federico Mei, Michela Dalmartello, Martina Bonifazi, Paola Bertuccio, Fabio Levi, Paolo Boffetta, Eva Negri, Carlo La Vecchia, Matteo Malvezzi","doi":"10.1111/resp.14328","DOIUrl":"https://doi.org/10.1111/resp.14328","url":null,"abstract":"Background and objective: Chronic obstructive pulmonary disease (COPD) incidence, prevalence, mortality and socioeconomic burden are considerable and vary across countries. The aim of the present study was to update the analysis of COPD mortality worldwide using data from the World Health Organization (WHO) up to 2019.Methods: We obtained COPD mortality and population data for 22 European countries and the European Union (EU) as a whole, 10 American countries and six other countries from the WHO mortality database. We calculated age-standardized mortality rates in both sexes and examined trends by country with joinpoint analysis between 1994 and 2019.Results: Between 2005-2007 and 2015-2017, overall COPD mortality decreased in EU men (-16.3%) but increased in women (12.7%) to reach rates of 14.0/100,000 in men and of 6.4/100,000 in women. In the United States, mortality declined in men to 21.3/100,000 but rose in women to 18.3/100,000. Mortality declined in most Latin American countries and all Asian countries, while an increase in Australian women was observed.Conclusion: A steady decrease in COPD mortality was observed in most of countries for men, whilst a different trend was observed in women in several countries. These trends are largely explained by changes in smoking habits, with an additional contribution of air pollution and occupational exposures. Despite past and ongoing tobacco control initiatives, this condition still remains a leading cause of death, in particular in countries with lower socio-demographic indices.","PeriodicalId":162871,"journal":{"name":"Respirology (Carlton, Vic.)","volume":" ","pages":"941-950"},"PeriodicalIF":6.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40613779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Long-term trends of COPD mortality: Gaps and opportunities. 慢性阻塞性肺病死亡率的长期趋势:差距和机会。

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-08-02 DOI: 10.1111/resp.14334

David M Mannino, Ruth Tal-Singer

引用次数: 1

A clinical short-cut to identifying short telomeres in idiopathic pulmonary fibrosis? 鉴别特发性肺纤维化短端粒的临床捷径?

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-08-28 DOI: 10.1111/resp.14355

Toby M Maher

引用次数: 0

Choosing and switching biological agents in severe asthma. 重症哮喘生物制剂的选择和转换。

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-09-26 DOI: 10.1111/resp.14377

Muhammad Adrish, Nicola A Hanania

{"title":"Choosing and switching biological agents in severe asthma.","authors":"Muhammad Adrish, Nicola A Hanania","doi":"10.1111/resp.14377","DOIUrl":"https://doi.org/10.1111/resp.14377","url":null,"abstract":"may also benefit from switching to a biologic that targets a different pathway. 6 Another common reason that has been linked to suboptimal response is nonad-herence to baseline controller and/or biologic therapy especially in patients who self-administer their medications at home. In such cases, these issues should be addressed without switching the biologic. 6 Reassessment of asthma biomarker and asthma phenotype are crucial in patients who have no response to initial therapy. Patients with no evidence of airway inflammation and those with neutrophil-predominant disease may benefit from stopping the current biologic and consideration of anti-TSLP, macrolide therapy or bronchial thermoplasty. 1,2,4,6 In summary, in the absence of head-to-head clinical trial comparing different biologic therapies, initial and subsequent biologic choice usually relies on factors such as asthma phenotype, biomarker profile and need for OCS use. All available biologics have shown efficacy in asthma with eosinophilic phenotype. Anti-TSLP is the only approved biologic for non-T2 severe asthma. Before switching to a different biologic, it is imperative first to address adherence to existing therapy, asthma triggers and comorbidities. Reassessment of asthma phenotype and revisiting biomarker profile should guide the next steps in choosing an alternative biologic.","PeriodicalId":162871,"journal":{"name":"Respirology (Carlton, Vic.)","volume":" ","pages":"926-928"},"PeriodicalIF":6.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33486724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Bronchiectasis: A pulmonary disease with systemic consequences. 支气管扩张:一种具有全身后果的肺部疾病。

IF 6.9

Respirology (Carlton, Vic.) Pub Date : 2022-11-01 Epub Date: 2022-09-13 DOI: 10.1111/resp.14370

Miguel Angel Martinez-Garcia, Oriol Sibila, Stefano Aliberti

{"title":"Bronchiectasis: A pulmonary disease with systemic consequences.","authors":"Miguel Angel Martinez-Garcia, Oriol Sibila, Stefano Aliberti","doi":"10.1111/resp.14370","DOIUrl":"https://doi.org/10.1111/resp.14370","url":null,"abstract":"could play a crucial role, 6 while Huang et al. observed that an increased serum concentration of desmosine (as part of systemic inflammation in bronchiectasis) was associated with an increased adjusted cardiovascular mortality in bronchiectasis patients. 10 The future therapeutic implications of this situation could be highly significant. Some authors have observed that both non-pharmacological treatments (such as muscle reha-bilitation and nutritional programs) and pharmacological treatments (such as statins, neutrophil elastase inhibitors, CXCR2 inhibitors, antibiotics and other immunomodula-tory treatments) 11 can reduce the level of some systemic proinflammatory molecules. However, no beneficial effect on bronchiectasis has been demonstrated from treatment of systemic inflammation, and, consequently, international guidelines do not recommend such interventions. Finally, some markers of systemic inflammation could also be used to predict treatment response. For example, the number or percentage of peripheral eosinophils could predict the response to biological or inhaled steroid treatments in bronchiectasis (as in the case of COPD), as already sug-gested by various authors. 12 In conclusion, systemic inflammation in bronchiectasis patients has been demonstrated in the past decade, and it could cause extrapulmonary damage, especially in terms of an increased risk of cardiovascular and metabolic/nutritional diseases. As highlighted by the EMBARC ( European Multi-centre Bronchiectasis Audit and Research Collaboration ) taskforce on research priorities, further studies are needed to identify biomarkers that can assist in risk stratification, tar-geted interventions and monitoring strategies, as well as the confirmation of a causal relationship between the presence of systemic inflammation (directly or through an increase in exacerbations of bronchial infection) and damage to several target organs.","PeriodicalId":162871,"journal":{"name":"Respirology (Carlton, Vic.)","volume":" ","pages":"923-925"},"PeriodicalIF":6.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33465555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2